1. Home
  2. SDEV vs MDXH Comparison

SDEV vs MDXH Comparison

Compare SDEV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stablecoin Development Corporation Common Stock

SDEV

Stablecoin Development Corporation Common Stock

N/A

Current Price

$3.66

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$0.58

Market Cap

68.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SDEV
MDXH
Founded
2000
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
68.7M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
SDEV
MDXH
Price
$3.66
$0.58
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.80
AVG Volume (30 Days)
★ 5.9M
195.2K
Earning Date
11-06-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 35.42
N/A
EPS
★ 2.77
N/A
Revenue
★ $370,000.00
N/A
Revenue This Year
N/A
$5.40
Revenue Next Year
N/A
$12.92
P/E Ratio
$0.97
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.78
$0.40
52 Week High
$3.40
$5.33

Technical Indicators

Market Signals
Indicator
SDEV
MDXH
Relative Strength Index (RSI) 82.32 43.94
Support Level $0.93 $0.51
Resistance Level N/A $0.75
Average True Range (ATR) 0.30 0.05
MACD 0.27 -0.01
Stochastic Oscillator 95.70 30.95

Price Performance

Historical Comparison
SDEV
MDXH

About SDEV Stablecoin Development Corporation Common Stock

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: